Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.35 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.34 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3869620 | 1.00 | BACE1 (0.39) | BACE1CTSSCTSKKLK5MAP1LC3B | |
| SCHEMBL3867460 | 0.83 | ALDH1A1 (0.34) | PPARAPOLB | |
| SCHEMBL3867464 | 0.83 | ALDH1A1 (0.34) | PPARAPOLB | |
| SCHEMBL23216984 | 0.81 | AAK1 (0.36) | AAK1CTSA | |
| SCHEMBL29854015 | 0.81 | AAK1 (0.36) | AAK1CTSA | |
| SCHEMBL1553332 | 0.77 | GPR88 (0.40) | BACE1CTSSCTSKMAP1LC3BMAP1LC3A | |
| SCHEMBL27603568 | 0.77 | CTSA (0.51) | CTSAPOLB | |
| SCHEMBL4883355 | 0.77 | CTSA (0.51) | CTSAPOLB | |
| SCHEMBL8615780 | 0.76 | CTSK (0.39) | CTSSCTSKATM | |
| SCHEMBL13118109 | 0.75 | CTSS (0.48) | CTSSCTSKPPARAATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149444-A1 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
| US-7514475-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| US-7504437-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504393-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20080255095-A1 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1362844-B1 | BENZYLAMINE ANALOGUE | BTG INT LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| US-20070037795-A1 | 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders | BTG INTERNATIONAL LIMITED (GB) | 2007-02-15 | — | — | US | disclosed |
| US-20070037793-A1 | 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders | BTG INTERNATIONAL LIMITED (GB) | 2007-02-15 | — | — | US | disclosed |
| US-20040067981-A1 | Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants | SANKYO COMPANY, LIMITED (JP) | 2004-04-08 | — | — | US | disclosed |
| EP-1362844-A1 | BENZYLAMINE ANALOGUE | Sankyo Company, Limited (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037793-A1 | 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders | CHRNA4, SLC6A4, DRD4 | BACE1 79/4885CTSS 771/4885CTSK 2518/4885 |
| US-20070037795-A1 | 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders | SLC6A4, SLC6A3, HTR4 | BACE1 61/4885CTSS 456/4885CTSK 1793/4885 |
| US-20040067981-A1 | Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants | ACHE, BACE1, CHRNA6 | BACE1 2/4885CTSS 824/4885CTSK 2096/4885 |
| US-20090149444-A1 | Benzylamine analogues | HTR4, DRD4, SLC6A4 | BACE1 60/4885CTSS 566/4885CTSK 2077/4885 |
| US-20080255095-A1 | Benzylamine analogues | NR4A3, NAT1, HRH4 | BACE1 2169/4885CTSS 4716/4885CTSK 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.